Executive Summary: Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-associated Organ Dysfunction in Children 2019

Authors:

Scott L. Weiss, MD, MSCE, FCCM (Co-Vice Chair); Mark J. Peters, MD, PhD (Co-Vice Chair); Waleed Alhazzani, MD, MSc, FRCP (Methodology Chair); Michael S. D. Agus, MD, FCCM, FAAP; Heidi R. Flori, MD, FAAP; David P. Inwald, MB, BCHir, FRCPCH, FFICM, PhD; Simon Nadel, MBBS, MRCP, FRCP; Luregn J. Schlapbach, FCICM, FMH-ICU, FMH-Paeds, FMH-Neonatology; Robert C. Tasker, MB BS, MA, AM, MD, FRCPCH, FRCP; Andrew C. Argent, MB BCH, MMed, MD (Paediatrics); Joe Brierley, MD, MA; Joseph Carcillo, MD; Enitan D. Carrol, MB ChB, MD, FRCPCH, DTMH; Christopher L. Carroll, MD, MS, FCCM, FAAP; Karen Choong, MB, BCH, FRCP(C) (methodologist); Jeffry J. Cies, PharmD, MPH, BCPS-AQ ID, BCPPS, FCCP, FCCM, FPPAG; Andrea T. Cruz, MD, MPH, FAAP; Daniele De Luca MD, PhD; Akash Deep, MB BS, MD, FRCPCH; Saul N. Faust, MA, MB BS, FRCPCH, PhD, FHEA; Claudio Flauzino De Oliveira, MD, PhD; Mark W. Hall, MD, FCCM, FAAP; Paul Ishimine, MD, FAAP; Etienne Javouhey, MD, PhD; Koen F. M. Joosten, PhD; Poonam Joshi, PhD; Oliver Karam, MD, PhD; Martin C. J. Kneyber, MD, PhD, FCCM; Joris Lemson, MD, PhD; Graeme MacLaren, MD, MSc, FCCM; Nilesh M. Mehta, MD; Morten Hylander Møller, MD, PhD; Christopher J. L. Newth, MD, ChB, FRCP, FRACP; Trung C. Nguyen, MD, FAAP; Akira Nishisaki, MD, MSCE, FAAP; Mark E. Nunnally, MD, FCCM (methodologist); Margaret M. Parker, MD, MCCM, FAAP; Raina M. Paul, MD, FAAP; Adrienne G. Randolph, MD, MS, FCCM, FAAP; Suchitra Ranjit, MD, FCCM; Lewis H. Romer, MD; Halden F. Scott, MD, MSCS, FAAP, FACEP; Lyvonne N. Tume, BS, MSN, PhD, RN; Judy T. Verger, RN, PhD, CPNP-AC, FCCM, FAAN; Eric A. Williams, MD, MS, MMM, FAAP; Joshua Wolf, MBBS, PhD, FRACP; Hector R. Wong, MD; Jerry J. Zimmerman, MD, PhD, FCCM; Niranjan Kissoon, MB BS, MCCM, FRCP(C), FAAP, FACPE (Co-Chair); Pierre Tissieres, MD, DSc (Co-Chair).
C.S. Mott Children’s Hospital, Ann Arbor, Michigan, USA

St. Mary’s Hospital, London, England, UK

Paediatric Critical Care Research Group, The University of Queensland and Queensland Children’s Hospital, Brisbane, Australia

Red Cross War Memorial Children’s Hospital and University of Cape Town, Cape Town, South Africa

Great Ormond Street Hospital for Children, London, England, UK

Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA

University of Liverpool, Liverpool, England, UK

Connecticut Children’s Medical Center, Hartford, Connecticut, USA

Duke Children’s, Durham, North Carolina, USA

St. Christopher’s Hospital for Children, Philadelphia, Pennsylvania, USA

Texas Children’s Hospital, Houston, Texas, USA

Paris South University Hospitals—Assistance Publique Hopitaux de Paris, Paris, France

King’s College Hospital, London, England, UK

University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK

The Latin America Sepsis Institute, São Paulo, Brazil

Nationwide Children’s Hospital, Columbus, Ohio, USA

Rady Children’s Hospital, San Diego, California, USA

Centre Hospitalier Universitaire de Lyon, Lyon, France

Erasmus University Medical Center, Rotterdam, Netherlands

All India Institute of Medical Sciences, New Delhi, India

Children’s Hospital of Richmond at VCU, Richmond, Virginia, USA

Beatrix Children’s Hospital, Groningen, Netherlands

Radboud University Medical Centre, Nijmegen, Netherlands

National University Health System, Singapore, and Royal Children’s Hospital, Melbourne, Australia

Rigshospitalet Hospital, Copenhagen, Denmark

Children’s Hospital of Los Angeles, Los Angeles, California, USA

New York University Langone Medical Center, New York, New York, USA

Stony Brook University, Stony Brook, New York, USA

Advocate Children’s Hospital, Park Ridge, Illinois, USA

Apollo Hospitals, Chennai, India

Johns Hopkins Children’s Center, Baltimore, Maryland, USA

Children’s Hospital Colorado, Aurora, Colorado, USA

University of the West of England, Bristol, England, UK
St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
Cincinnati Children’s Hospital, Cincinnati, Ohio, USA
Seattle Children’s Hospital, Seattle, Washington, USA
British Columbia Children’s Hospital, Vancouver, British Columbia, Canada
Institute of Integrative Biology of the Cell-CNRS, CEA, Univ Paris Sud, Gif-sur-Yvette, France
Physiopathology and Therapeutic Innovation Unit—INSERM U999, South Paris-Saclay University, Paris, France
College of Nursing, University of Iowa, Iowa City, Iowa, USA

For additional information regarding this article, email weissS@email.chop.edu

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions on this journal’s website.

The following sponsoring organizations with formal liaison appointees endorse this guideline:
American Academy of Pediatrics; American Association of Critical-Care Nurses; American College of Emergency Physicians; American Thoracic Society; Canadian Critical Care Society; European Society of Intensive Care Medicine; European Society of Paediatric and Neonatal Intensive Care; Scandinavian Society of Anaesthesiology and Intensive Care Medicine; Society of Critical Care Medicine; UK Sepsis Trust; World Federation of Pediatric Intensive and Critical Care Societies

The following non-sponsoring organizations (without formal liaison appointees) endorse this guideline: TBD

Disclosures: S. Weiss and M. Peters served as arbiters for conflict interest management and adjudication throughout the guidelines process following standard operating procedures set forth by SCCM and endorsed by ESICM. Disclosures were collected throughout guidelines development with verbal disclosures and more formally using SCCM’s conflict of interest system where indicated. The following disclosures were provided by the authors: S. Weiss participates as a member of the Shock Society; M. Peters serves as Vice Chair of the UK PICS study group; M. Agus is active as a volunteer in the American Academy of Pediatrics, Pediatric Academic Societies, American Pediatric Society, Society for
Pediatric Research, and The American Society for Clinical Investigation; H. Flori is a Michigan and California state chapter executive board member for the American Thoracic Society (ATS), participates in the Pediatric Acute Lung Injury and Sepsis Investigators Network, Federal funding from and grant funding from Gerber Corporation; S. Nadel is the current President of the European Society of Pediatric and Neonatal Intensive Care Medicine (ESPNIC); J. Brierly serves as Past President of ESPNIC; J. Carcillo XXXX; E. Carrol is a member of the NICE Diagnostic Advisory Committee and scientific panels through the National Institutes for Health Research; I. Cheifetz is a volunteer for the American Association for Respiratory Care and the American Thoracic Society, he is an advisor to Philips, and a contributor to Up-to-Date; J. Cies received grants and honoraria from Allergan, Merck, and Thermo Fisher Scientific and is a consultant for Atlantic Diagnostic Lab Liaison committee; A. Cruz has provided testimony for legal cases involving children with tuberculosis-related meningitis and is an associate editor for Pediatrics; D. De Luca serves as President-elect on the Executive Committee of ESPNIC, he served as a consultant and lecturer on the external advisory board and received research and educational grants from Chiesi Farmaceutici S.p.A and AbbVie Inc., and travel grants from AbbVie, he has been a lecturer for Philips, Radiometer, and Waire; S. Faust served as chair of the UK NICE Guideline Committee for Sepsis in Children and Adults published in 2016 and for Lyme disease published in 2018, serves as a regional representative to the UK NHS England Clinical Reference Group for commissioning paediatric specialist medicine care (immunology and infection); M. Hall serves on a data safety monitoring board for sepsis trials for La Jolla Pharmaceuticals, American Thoracic Society editor for an on-line journal club, and serves on a sub-board for the American Board of Pediatrics; P. Ishimine serves on various boards: American Board of Emergency Medicine, and is a member of the American College of Emergency Physicians; E. Javouhey received funding from the CSL Behring company for a trial on intravenous immunoglobulins in toxic shock syndrome in children; O. Karam is the chair of BloodNet; M. Kneyber is scientific chair of ESPNIC; G. MacLaren serves on the Executive Committee of the Extracorporeal Life Support Organization; N. Mehta is the President of the American Society of Parenteral and Enteral Nutrition; M. H. Møller is a board member for Science Systems and Applications, Inc.; C. Newth provides consulting services to Philips Research North America for PICU monitoring devices; A. Nishisaki is affiliated with the Society for Simulation in Healthcare and the International Society for Pediatric Simulation, he has also a portion of his time supported by a grant from Nihon Kohden device development for capillary refill time measurement; M. Nunnally reports service on committees and board seats for the SCCM’s American College of Critical Care Medicine, Society of Critical Care Anesthesiologists, and the American Society of Anesthesiologists, International Anesthesia Research Society; A. Randolph through her institution has research support from Genentech, Inc. for influenza biomarkers, served as a consultant for Bristol Myers Squibb in 2017 pediatric sepsis trial
design, and is a consultant for La Jolla Pharmaceuticals design of pediatric septic shock trial angiotensin II; S. Ranjit is Chancellor of the College of Pediatric Critical Care Medicine India; L. Tume is Nursing President for ESPNIC and serves on the UK PICS Scientific and Education Committees; J. Verger serves on the American Association of Critical-Care Nurses Governance Committee and special interest groups related to acute care nursing; J. Wolf receives research support from Merck & Company, Astellas Pharma, and has grant support from Karius, Inc., Empatica Inc., and Bluespark Technologies; J. Zimmerman received biomarker research funding from Immunexpress and is Past President of SCCM; P. Tissieres provides consulting services for Baxter, Inc. acute therapies, Bristol-Myers Squibb Company, Chiesi Farmaceutici S.p.A., Faron Pharmaceuticals, has research grants from bioMérieux, funding from La Jolla Pharmaceuticals, Chiesi Farmaceutici S.p.A., and is President-elect of ESPNIC. All other authors, staff, and consultants have indicated they have no conflicts to report.

**Disclaimer:** The Society of Critical Care Medicine guidelines are intended for general information only, are not medical advice, and do not replace professional advice, which should be sought for any medical condition. The full disclaimer for guidelines can be accessed at https://www.sccm.org/Research/Guidelines/Guidelines.

**Funding:** These guidelines were solely funded by the European Society of Intensive Care Medicine and the Society of Critical Care Medicine.
INTRODUCTION

In 2001, the Surviving Sepsis Campaign (SSC) began to develop evidenced-based guidelines and recommendations for the resuscitation and management of patients with sepsis. With the 2016 edition, the Society of Critical Care Medicine and European Society of Intensive Care Medicine recommended a separate task force be dedicated to guideline formulation for children.

The objective of the Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-associated Organ Dysfunction in Children is to provide guidance for the care of children with septic shock and other sepsis-associated organ dysfunction. Recommendations are intended to guide "best practice" rather than to establish a treatment algorithm or to define standard of care, and cannot replace the clinician’s decision-making capability when presented with a patient’s unique set of clinical variables.

METHODS

This executive summary briefly reviews the methodology, with additional details provided in the complete guidelines document published in Pediatric Critical Care Medicine <add link to url> and Intensive Care Medicine <add link to url>.

Definitions and Scope

The scope of these guidelines includes all patients from ≥37 weeks’ gestation at birth to 18 years with severe sepsis or septic shock as defined by the 2005 International Pediatric Sepsis Consensus Conference (1) or inclusive of severe infection leading to
life-threatening organ dysfunction. Practically, all children with septic shock or other sepsis-associated acute organ dysfunction are included in this scope with the exception of premature babies who have distinct pathology, biology, and therapeutic considerations. Even though these guidelines are not intended to address the management of infection when there is not associated acute organ dysfunction, we recognize that sepsis exists as a spectrum and some children without known acute organ dysfunction may still benefit from similar therapies as those with known organ dysfunction.

The intended users of these guidelines are health professionals caring for children in a hospital, emergency, or other acute care setting. However, many of the recommendations are likely to apply to the care of children in other settings and will need to be adapted to specific environments and resource availability. In addition, these guidelines were largely developed without consideration of the availability of health care services, though we realize that medical care is necessarily carried out within the confines of locally available resources.

Selection and Organization of Panel Members

The selection of panel members was based on their expertise in specific aspects of pediatric sepsis, with broad International and multi-professional representation representing diverse geographic settings and health care systems. Three members from the lay public were also included.

Panelists were divided into the following subgroups: 1) recognition and management of infection, 2) hemodynamics and resuscitation, 3) ventilation, 4)
endocrine and metabolic therapies, and 5) adjunctive therapies. A sixth subgroup reviewed research priorities. Each subgroup was supported by a trained methodologist.

**Question Development and Outcome Prioritization**

The panel selected topics addressed in the 2016 adult SSC guidelines that were relevant to children, as well as other key topics important to children with sepsis. The PICO format, which describes the population (P), intervention (I), control (C), and outcomes (O), was used for all guideline questions. For practical reasons, we excluded several issues pertaining to general acute or critical illness that were not specific for sepsis (e.g., head-of-bed positioning during invasive mechanical ventilation) and have been addressed in other guidelines (e.g., Pediatric Acute Lung Injury Consensus Conference [PALICC]) (2). However, topics with particular relevance to children with septic shock or other sepsis-associated acute organ dysfunction were included in this guideline, even if there was evaluation of similar or overlapping topics in previous publications. The final list of PICO questions is provided as eTable 1 in the supplement to the complete guidelines.

**Search Strategy and Evidence Summation**

Professional medical librarians assisted with the literature searches and utilized a combination of controlled vocabulary (e.g., “sepsis,” “bacterial infections,” “critical illness,” “intensive care units,” “pediatrics”), key words (e.g., “toxic shock,” “blood poisoning,” “acute infection,” “PICU,” “child”), and qualifiers specific to each PICO question. Only English language studies were included. As this was the inaugural
version of these guidelines for children, all publications through May 1, 2017 were considered. Key studies published after the conclusion of the initial literature search were incorporated into the evidence synthesis if identified by panel members as important and relevant even if they were not part of the initial literature review.

**Formulation of Recommendations**

The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) principles guided the assessment of quality of evidence from high to very low and were used to determine the strength of recommendations. The GRADE approach to assess the quality of evidence is based on the evaluation of six domains: 1) risk of bias, 2) inconsistency, 3) indirectness, 4) imprecision, 5) publication bias, and 6) other criteria, followed by assessment of the balance between benefit and harm, patients’ values and preferences, cost and resources, and feasibility and acceptability of the intervention (3).

The panel initially considered research focused on pediatric patients using the following hierarchy of evidence: systematic reviews, randomized controlled trials, prospective observational studies, retrospective observational studies, case-control studies, and large case series. Research focusing on children with septic shock and other sepsis-associated organ dysfunction was prioritized, though studies inclusive of more general pediatric populations (e.g., all PICU patients) were considered for some questions on a case-by-case basis. If there were insufficient data in children with sepsis or general pediatric illness, data from adult studies was considered using a pre-specified framework to guide appropriateness of indirect evidence.
Each of the subgroups used the Evidence-to-Decision (EtD) framework to facilitate transition from evidence to recommendations. The EtD framework ensured that panel members took into consideration not only the quality of evidence and magnitude of effect, but also balance between benefits and harms, patients’ values and preferences, resources, cost, acceptability, and feasibility (4).

We classified recommendations as strong or weak using the language “We recommend…” or “We suggest…,” respectively. We judged a strong recommendation in favor of an intervention to have desirable effects of adherence that will clearly outweigh the undesirable effects. The implications of calling a recommendation strong are that most patients would accept that intervention and that most clinicians should use it in most situations. However, a strong recommendation does not imply a standard of care, and circumstances may exist in which a strong recommendation cannot or should not be followed for an individual patient. We judged a weak recommendation in favor of an intervention to have desirable consequences of adherence that will probably outweigh the undesirable consequences, but confidence is diminished either because the quality of evidence was low or the benefits and risks were closely balanced. We anticipate that a weak recommendation, while still relevant for most patients in most settings, will be more heavily influenced by clinical circumstances and patients’ values than a strong recommendation. We permitted strong recommendations (for or against an intervention) based on low or very low quality of evidence when there was either strong physiologic rationale to support benefit or uncertain benefit but very likely or certain harm (5).

Best practice statements (BPS) were offered when the evidence could not be summarized using GRADE methodology but the benefit or harm was deemed
unequivocal. In addition, when evidence was insufficient to make a recommendation, but the panel felt that some guidance may be appropriate, we issued an “in our practice” statement. The “in our practice” statements were developed through a survey of all panelists in that group to ascertain their state of current practice in an attempt to describe current variation in care. These should not be construed as recommendations.

Voting Process

Panel members convened to review evidence and discuss recommendations at key international meetings, a stand-alone meeting in November 2018, and numerous web-based conference calls. Panelists then indicated agreement or disagreement (or abstention if conflict of interest present) with each recommendation. Up to 3 rounds of voting were conducted in an attempt to achieve consensus. Acceptance of a statement required votes from 75% of panel members with a 80% agreement threshold.

Conflict of Interest Policy

Conflict-of-interest disclosures were sought from all panelists prior to commencing activities, with updates annually and as needed. There was no industry input into or support of the guideline development process. Only librarians and a supporting project manager received compensation for their work.

RECOMMENDATIONS

The consensus recommendations of the *Surviving Sepsis Campaign* 

*International Guidelines for the Management of Septic Shock and Sepsis-associated*
Organ Dysfunction in Children are summarized in Table 1 of this executive summary. The rationale and evidence profiles supporting each recommendations are presented in the complete guidelines <add link to URL>s. The panel provided 76 statements on the management and resuscitation of children with septic shock and other sepsis-associated organ dysfunction, including 5 strong recommendations, 49 weak recommendations, and 9 best practice statements. For 13 questions, no recommendations could be made, but, for 10 of these, “in our practice” statements were provided. In addition, 49 research priorities were identified (see complete guidelines).

CONCLUSIONS

Although most aspects of care had relatively low quality of evidence resulting in the frequent issuance of weak recommendations, these guidelines regarding the management of children with septic shock and other sepsis-associated organ dysfunction should provide a foundation for consistent care to improve outcomes and inform future research.
REFERENCES


